Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Clarksterh who wrote (1309)	11/22/2004 12:20:01 PM
From: NeuroInvestment	Read Replies (2) \| Respond to of 1386

Clark: I think you are being overly harsh in terms of your classifying this as 'data mining'. The Stroop was one of six tests given, and the results were significant at p=.01. I did not expect that to occur--but if I had to choose one domain where a trend would have been expected (given post-CABG pt complaints of slowed decision making and information processing), this is it. Had they come out with some third-order 'finding' like (I'm making this up): 'male CABG patients over 62 but under 64 showed improvement on the Stroop at six weeks, significant at .049', where there are a host of covariates thrown in, your criticism would be justified. But they didnt. If it's data mining, they did not have to dig deep to find something of value. Trailmaking is a paper and pencil test, and was not given. Both Trails and the Stroop tap frontal lobe functions, though Trails adds in a visual scan/motor speed component. So far as I am aware, no previous CABG trial did pre-post comparisons using the Stroop--in fact I am not aware of any drug producing a positive neuroprotectant effect in CABG--so I consider this an early but promising finding. Certainly it is not ready for PhIII, but Phase IIb is a viable option. From my perspective, I had hoped for a trend showing a signal of effect. This finding bettered that expectation. Harry Tracy NeuroInvestment